Abstract
Initial attempts to unravel the molecular mechanism of insulin resistance have strongly suggested that a defect responsible for insulin resistance in the majority of patients lies at the post-receptor level of insulin signaling. Subsequent studies in insulin-resistant animal models and humans have consistently demonstrated a reduced strength of insulin signaling via the IRS-1–PI 3-kinase pathway, resulting in diminished glucose uptake and utilization in insulin target tissues. However, the nature of the triggering event(s) remains largely enigmatic. Two separate, but likely complementary, mechanisms have recently emerged as a potential explanation. First, it became apparent that serine phosphorylation of IRS proteins can reduce their ability to attract PI 3-kinase, thereby minimizing its activation. A number of serine kinases that phosphorylate serine residues of IRS-1 and weaken insulin signal transduction have been identified. Additionally, mitochondrial dysfunction has been suggested to trigger activation of several serine kinases, leading to a serine phosphorylation of IRS-1. Second, a distinct mechanism involving increased expression of p85α(alpha) has also been found to play an important role in the pathogenesis of insulin resistance. Conceivably, a combination of both increased expression of p85α(alpha) and increased serine phosphorylation of IRS-1is needed to induce clinically apparent insulin resistance.
Keywords
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Olefsky JM. The insulin receptor: a multifunctional protein. Diabetes. 1990;39:1009–16.
Reaven GM. Role of insulin resistance in human disease. Diabetes. 1998;37:1595–607.
DeFronzo RA. The triumvirate: beta-cell, muscle, liver. A collision responsible for NIDDM. Diabetes. 1988;37:667–87.
Bell GI, Burant CF, Takeda J, Gould GW. Structure and function of mammalian facilitative sugar transporters. J Biol Chem. 1993;268:19161–4.
Shepherd PR, Kahn BB. Glucose transporters and insulin action. N Engl J Med. 1999;341:248–57.
Cheatham B. Phosphatidylinositol 3-kinase activation is required for insulin stimulation of pp70S6 kinase, DNA synthesis, and glucose transporter translocation. Mol Cell Biol. 1994;14:4902–11.
Shepherd PR, Nave BT, Siddle K. Insulin stimulation of glycogen synthesis and glycogen synthase activity is blocked by wortmannin and rapamycin in 3T3-L1 adipocytes: evidence for the involvement of phosphoinositide 3-kinase and p70 ribosomal protein-S6 kinase. Biochem J. 1995;305:25–8.
Lazar D. Mitogen-activated kinase kinase inhibition does not block the stimulation of glucose utilization by insulin. J Biol Chem. 1995;270:20801–7.
Sutherland C, Waltner-Law M, Gnudi L, Kahn BB, Granner DK. Activation of the Ras Mitogen-activated protein kinase-ribosomal protein kinase pathway is not required for the repression of phosphoenolpyruvate carboxykinase gene transcription by insulin. J Biol Chem. 1998;273:3198–204.
Bandyopadhyay GK, Standaert ML, Zhao L, Yu B, Avignon A, Galloway L, Karnam P, Moscat J, Farese RV. Activation of protein kinase (α, β, and ξ) by insulin in 3T3-L1 cells: transfection studies suggest a role for PKC-zeta in glucose transport. J Biol Chem. 1997;272:2551–8.
Jiang ZY, Lin Y-W, Clemont A, Feener EP, Hein KD, Igarashi M, Yamauchi T, White MF, King GL. Characterization of selective resistance to insulin signaling in the vasculature of obese Zucker (fa/fa) rats. J Clin Invest. 1999;104:447–57.
Cusi K, Maezono K, Osman A, Pendergrass M, Patti ME, Pratipanawatr T, DeFronzo RA, Kahn CR, Mandarino LJ. Insulin resistance differentially affects the PI 3-kinase- and MAP kinase-mediated signaling in human muscle. J Clin Invest. 2000;105:311–20.
Montagnani M, Golovchenko I, Kim I, Koh GY, Goalstone ML, Mundhekar AN, Johansen M, Kucik DF, Quon MJ, Draznin B. Inhibition of phosphatidylinositol 3-kinase enhances mitogenic action of insulin in endothelial cells. J Biol Chem. 2002;277:1794–9.
Wang C, Gurevich I, Draznin B. Insulin affects vascular smooth muscle cell phenotype and migration via distinct signaling pathways. Diabetes. 2003;52:2562–9.
Sartipy P, Loskutoff DJ. Monocyte chemoattractant protein 1 in obesity and insulin resistance. Proc Natl Acad Sci U S A. 2003;100:7265–70.
Ginsberg H. Insulin resistance and cardiovascular disease. J Clin Invest. 2000;106:453–8.
Shulman GI. Cellular mechanisms of insulin resistance in humans. Am J Cardiol. 1999;84:3J–10J.
Birnbaum MJ. Turning down insulin signaling. J Clin Invest. 2001;108:655–9.
Aguirre V, Werner ED, Giraud J, Lee YH, Shoelson SE, White MF. Phosphorylation of Ser307 in insulin receptor substrate-1 blocks interactions with the insulin receptor and inhibits insulin action. J Biol Chem. 2002;277:1531–7.
Pessin JE, Saltiel AR. Signaling pathways in insulin action: molecular targets of insulin resistance. J Clin Invest. 2000;106:165–9.
White MF. Insulin signaling in health and disease. Science. 2003;302:1710–1.
Semple RK. How does insulin resistance arise, and how does it cause disease? Human genetic lessons. Eur J Endocrinol. 2016;174:R209–23.
Cheatham B, Kahn CR. Insulin action and the insulin signaling network. Endocr Rev. 1995;16:117–41.
Kahn CR. Insulin action, diabetogenes, and the cause of type 2 diabetes. Diabetes. 1994;43:1066–84.
Ullrich A, Bell JR, Chen EY, Herrera R, Petruzzelli IM, Dull TJ, Gray A, Coussens L, Liao Y-C, Tsubokawa M, Mason A, Seeburg PH, Grunfeld C, Rosen OM, Ramachandran J. Human insulin receptor and its relationship to the tyrosine kinase family of oncogenes. Nature. 1985;313:756–61.
Ebina Y, Ellis L, Jarnagin K, Edery M, Grat L, Clauser E, Ou J-H, Masiarz F, Kan YW, Goldfine ID, Roth RA, Rutter WJ. The human insulin receptor cDNA. The structural basis for hormone-activated transmembrane signaling. Cell. 1985;40:747–58.
Seino S, Seino M, Nishi S, Bell GI. Structure of human insulin receptor gene and characterization of its promoter. Proc Natl Acad Sci U S A. 1989;86:114–8.
Kasuga M, Karisson FA, Kahn CR. Insulin stimulates the phosphorylation of the 95,000 Dalton subunit of its own receptor. Science. 1982;215:185–7.
Wilden PA, Siddle K, Haring E, Backer JM, White MF, Kahn CR. The role of insulin receptor-kinase domain autophosphorylation in receptor-mediated activities. J Biol Chem. 1992;267:13719–27.
De Meyts P, Chistoffersen CT, Torquist H, Seedorf K. Insulin receptors and insulin action. Curr Opin Endocrinol Diabetes. 1996;3:369–77.
Rhodes CJ, White MF. Molecular insights into insulin action and secretion. Eur J Clin Invest. 2002;32(Suppl 3):3–13.
White MF, Shoelson SE, Keutmann H, Kahn CR. A cascade of autophosphorylation in the beta subunit activates phosphotransferase of the insulin receptor. J Biol Chem. 1988;263:2969–80.
Tornqvist HE, Avruch J. Relationship of site-specific beta subunit tyrosine autophosphorylation to insulin activation of the insulin receptor (tyrosine) protein kinase activity. J Biol Chem. 1988;263:4593–601.
Myers MG Jr, White MF. Insulin signal transduction and the IRS proteins. Annu Rev Pharmacol Toxicol. 1996;36:615–58.
Paz K, Voliovitch H, Hadari YR, Roberts CT, LeRoith D, Zick Y. Interaction between the insulin receptor and its downstream effectors. J Biol Chem. 1996;271:6998–7003.
Kolterman OG, Insel J, Saekow M, Olefsky JM. Mechanisms of insulin resistance in human obesity: evidence for receptor and post-receptor defects. J Clin Invest. 1980;65:1272–84.
Marshal S, Olefsky JM. Effects if insulin incubation on insulin binding, glucose transport, and insulin degradation by isolated rat adipocytes. Evidence for hormone-induced desensitization at the receptor and post-receptor level. J Clin Invest. 1980;66:763–72.
Haring HU. The insulin receptor: signaling mechanism and contribution to the pathogenesis of insulin resistance. Diabetologia. 1991;34:848–61.
Petersen KF, Shulman GI. Etiology of insulin resistance. Am J Med. 2006;119:10S–6S.
Vivanco I, Sawyers CL. The phosphatidylinositol 3-kinase AKT pathway in human cancer. Nat Rev Cancer. 2002;2:489–501.
Munster PN, Marchion DC, Basso AD, Rosen N. Degradation of HER2 by ansamycins includes growth arrest and apoptosis in cells with HER2 overexpression via HER3, phosphatidylinositol 3′-kinase-Akt-dependent pathway. Cancer Res. 2002;62:3132–7.
Amaravadi R, Thompson GB. The survival kinases AKT and PIM as potential pharmacological targets. J Clin Invest. 2005;115:2618–24.
Ali IU, Schriml LM, Dean M. Mutational spectra of PTEN/MMAC1 gene: a tumor suppressor with lipid phosphatase activity. J Natl Cancer Inst. 1999;91:1922–32.
Kahn BB, Flier JS. Obesity and insulin resistance. J Clin Invest. 2000;106:473–81.
LeRoith D, Zick Y. Recent advances in our understanding of insulin action and insulin resistance. Diabetes Care. 2001;24:588–97.
Qiao L, Goldberg JL, Russell JC, Sun XJ. Identification of enhanced serine kinase activity in insulin resistance. J Biol Chem. 1999;274:10625–32.
Um SH, Frogerio F, Watanabe M, Picard F, Joaquin M, Sticker M, Fumagalli S, Allegrini PR, Kozma SC, Auwerx J, Thomas G. Absence of S6K1 protects against age- and diet-induced obesity while enhancing insulin sensitivity. Nature. 2004;431:200–5.
Patti M-E, Kahn BB. Nutrient sensor links obesity with diabetes risk. Nat Med. 2004;10:1049–50.
Qiao L, Zhande R, Jetton TL, Zhou G, Sun XJ. In vivo phosphorylation of insulin receptor substrate 1 at serine 789 by a novel serine kinase in insulin-resistant rodents. J Biol Chem. 2002;277:26530–9.
Shah OJ, Wang Z, Hunter T. Inappropriate activation of the TSC/Rheb/mTOR/S6K cassette induces IRS1/2 depletion, insulin resistance, and cell survival deficiencies. Curr Biol. 2004;14:1650–6.
Ueno M, Carvalheira JBC, Tambascia RC, Bezzera RMN, Amara ME, Carneiro EM, Folli F, Franchini KG, Saad MJA. Regulation of insulin signaling by hyperinsulinemia: role of IRS-1/2 serine phosphorylation and mTOR/p70 S6K pathway. Diabetologia. 2005;48:506–18.
Haruta T, Uno T, Kawahara J, Takano A, Egawa K, Sharma PM, Olefsky JM, Kobayashi M. A rapamycin-sensitive pathway down-regulates insulin signaling via phosphorylation and proteasomal degradation of insulin receptor substrate-1. Mol Endocrinol. 2000;14:783–94.
Tremblay F, Marette A. Amino acid and insulin signaling via the mTOR/p70 S6 kinase pathway. A negative feedback mechanism leading to insulin resistance in skeletal muscle. J Biol Chem. 2001;276:38052–60.
Harrington LS, Findlay GM, Gray A, Tolkacheva T, Wigfield S, Rebholz H, Barnett J, Leslie NR, Cheng S, Shepherd PR, Gout I, Downes CP, Lamb RE. The TSC1-2 tumor suppressor controls insulin-PI3K signaling via regulation of IRS proteins. J Cell Biol. 2004;166:213–23.
Hirosumi J, Tuncman G, Chang L, Gorzun CZ, Uysal KT, Maeda K, Karin M, Hotamisligil GS. A central role for JNK in obesity and insulin resistance. Nature. 2002;420:333–6.
Gao Z, Zhang X, Zuberi A, Hwang D, Quon MJ, Lefevre M, Ye J. Inhibition of insulin sensitivity by free fatty acids requires activation of multiple serine kinases in 3T3-L1 adipocytes. Mol Endocrinol. 2004;18:2024–34.
Nguyen MTA, Satoh H, Favelyukis S, Babendure JL, Imamura T, Sbodio JI, Zalevsky J, Dahiyat B, Chi N-W, Olefsky JM. JNK and TNF-α mediate free fatty acid-induced insulin resistance in 3T3-L1 adipocytes. J Biol Chem. 2005;280:35361.
Bandyopadhyay GK, Yu JG, Ofrecio J, Olefsky JM. Increased p85/55/50 expression and decreased phosphatidylinositol 3-kinase activity in insulin-resistant human skeletal muscle. Diabetes. 2005;54:2351–9.
Lee YH, Giraud J, Davis RJ, White MF. C-Jun N-terminal kinase (JNK) mediates feedback inhibition of the insulin signaling cascade. J Biol Chem. 2003;278:2896–902.
Perseghin G, Petersen K, Shulman GI. Cellular mechanism of insulin resistance: potential links with inflammation. Int J Obes Relat Metab Disord. 2003;27(Suppl 3):S6–11.
Gao Z, Hwang D, Bataille F, Lefevre M, York D, Quon MJ, Ye J. Serine phosphorylation of insulin receptor substrate 1 by inhibitor kB kinase complex. J Biol Chem. 2002;277:48115–21.
Kim JK, Kim Y-J, Fillmore JJ, Chen Y, Moore I, Lee J, Yuan M, Li ZW, Karin M, Perret P, Shoelson SE, Shulman GI. Prevention of fat-induced insulin resistance by salicylate. J Clin Invest. 2001;108:437–46.
Hundal RS, Petersen KF, Mayerson AB, Rahdhawa PS, Inzucchi S, Shoelson SE, Shulman GI. Mechanism by which high-dose aspirin improves glucose metabolism in type 2 diabetes. J Clin Invest. 2002;109:1321–6.
Hotamisligil GS, Spiegelman BM. Tumor necrosis factor alpha: a key component of the obesity-diabetes link. Diabetes. 1994;43:1271–8.
Qi C, Pekala PH. Tumor necrosis factor-alpha-induced insulin resistance in adipocytes. Proc Soc Exp Biol Med. 2000;223:128–35.
Hotamisligil GS, Shargill NS, Spiegelman BM. Adipose expression of tumor necrosis factor-alpha: direct role in obesity-linked insulin resistance. Science. 1993;259:87–91.
Uysal KT, Wiesbrock SM, Marino MW, Hotamisligil GS. Protection from obesity-induced insulin resistance in mice lacking TNF-alpha function. Nature. 1997;389:610–4.
Hotamisligil GS, Peraldi P, Budavari A, Ellis R, White MF, Spiegelman BM. IRS-1-mediated inhibition of insulin receptor tyrosine kinase activity in TNF-alpha and obesity-induced insulin resistance. Science. 1996;271:665–8.
Lowell BB, Shulman GI. Mitochondrial dysfunction and type 2 diabetes. Science. 2005;307:384–7.
Petersen KF, Befroy D, Dufour S, Dziura J, Ariyan C, Rothman DL, DiPietro L, Cline GW, Shulman GI. Mitochondrial dysfunction in the elderly: possible role in insulin resistance. Science. 2003;300:1140–2.
Petersen KF, Dufour S, Befroy D, Garcia R, Shulman GI. Impaired mitochondrial activity in the insulin-resistant offspring of patients with type 2 diabetes. N Engl J Med. 2004;350:664–71.
Li Y, Soos TJ, Li X, Wu J, Degennaro M, Sun X, Littman DR, Birnbaum MJ, Polakiewicz RD. Protein kinase θ inhibits insulin signaling by phosphorylating IRS1 at Ser(1101). J Biol Chem. 2004;279:45304–7.
Bell KS, Shcmitz-Peiffer C, Lim-Fraser M, Biden TJ, Cooney GJ, Kraegen EW. Acute reversal of lipid-induced muscle insulin resistance is associated with rapid alteration in PKC-θ localization. Am J Physiol Endocrinol Metab. 2000;279:E1196–201.
Kim JK, Fillmore JJ, Sunshine MJ, Albrecht B, Higashimori T, Kim DW, Liu ZX, Soos TJ, Cline GW, O’Brien WR, Littman DR, Shulman GI. PKC-θ knockout mice are protected from fat-induced insulin resistance. J Clin Invest. 2004;114:823–7.
Itani SI, Pories WJ, Macdonald KG, Dohm GL. Increased protein kinase C θ in skeletal muscle of diabetic patients. Metabolism. 2001;50:553–7.
Raught B, Gingras AC, Sonenberg N. The target of rapamycin (TOR) proteins. Proc Natl Acad Sci U S A. 2001;98:7037–44.
Rohde J, Heitman J, Cardenas ME. The TOR kinases link nutrient sensing to cell growth. J Biol Chem. 2001;276:9583–6.
Khamzina L, Veilleux A, Bergeron S, Marette A. Increased activation of the mammalian target of rapamycin pathway in liver and skeletal muscle of obese rats: possible involvement in obesity-linked insulin resistance. Endocrinology. 2005;146:1473–81.
Trembley F, Gagnon A, Veilleux A, Sorisky A, Marette A. Activation of the mammalian target of rapamycin pathway acutely inhibits insulin signaling to Akt and glucose transport in 3T3-L1 and human adipocytes. Endocrinology. 2005;146:1328–37.
Burnett PE, Barrow RK, Cohen NA, Snyder SH, Sabatini DM. RAFT1 phosphorylation of the translational regulators p70S6 kinase and 4E-BP1. Proc Natl Acad Sci U S A. 1998;95:1432–7.
Hara K, Yonezawa K, Kozlowski MT, Sugimoto T, Andrabi K, Weng OP, Kasuga M, Nishimoto I, Avruch J. Regulation of eIF-4E BP1 phosphorylation by mTOR. J Biol Chem. 1997;272:26457–63.
Isotani S, Hara K, Tokunaga C, Inoue H, Avruch J, Yonezawa K. Immunopurified mammalian target of rapamycin phosphorylates and activates p70S6 kinase α in vitro. J Biol Chem. 1999;274:34493–8.
Hara K, Maruki Y, Long X, Yoshino K, Oshiro N, Hidayat S, Tokunaga C, Avruch J, Yonezawa K. Raptor, a binding partner of target of rapamycin (TOR), mediates TOR action. Cell. 2002;110:177–89.
Kim DH, Sarbassov DD, Ali SM, King JE, Latek RR, Erdjument-Bromage H, Tempst P, Sabatini DM. mTOR interacts with raptor to form a nutrient-sensitive complex that signals to the cell growth machinery. Cell. 2002;110:163–75.
Jacinto E, Loewith R, Scmidt A, Lin S, Ruegg MA, Hall A, Hall MN. Mammalian TOR complex 2 controls the actin cytoskeleton and is rapamycin sensitive. Nat Cell Biol. 2004;6:1122–8.
Loewith R, Jacinto E, Wullschleger S, Lorberg A, Crespo JL, Bonenfant D, Oppliger W, Jenoe P, Hall MN. Two TOR complexes, only one of which is rapamycin sensitive, have distinct roles in cell growth control. Mol Cell. 2002;10:457–68.
Sabrassov DD, Ali SM, Kim DH, Guertin DA, Latek RR, Erdjument-Bromage H, Tempst P, Sabatini DM. Rictor, a novel binding partner of mTOR, defines a rapamycin-insensitive and raptor-independent pathway that regulates the cytoskeleton. Curr Biol. 2004;14:1296–302.
Sabrassov DD, Guertin DA, Ali SM, Sabatini DM. Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex. Science. 2005;307:1098–101.
Nave BT, Ouwens M, Withers DJ, Alessi DR, Shepherd PR. Mammalian target of rapamycin is a direct target for protein kinase B: identification of a convergence point for opposing effects of insulin and amino-acid deficiency on protein translation. Biochem J. 1999;344:427–31.
Scott PH, Brunn GJ, Kohn AD, Roth RA, Lawrence JC Jr. Evidence of insulin-stimulated phosphorylation and activation of the mammalian target of rapamycin mediated by a protein kinase B signaling pathway. Proc Natl Acad Sci U S A. 1998;95:7772–7.
Hinault C, Mothe-Satney I, Gautier N, Lawrence JC Jr, Van Obberghen E. Amino acids and leucine allow insulin activation of the PKB/mTOR pathway in normal adipocytes treated with wortmannin and in adipocytes from db/db mice. FASEB J. 2004;18:1894–6.
Pham P-TT, Heydrick SJ, Fox HL, Kimball SR, Jefferson LS Jr, Lynch CJ. Assessment of cell-signaling pathways in the regulation of mammalian target of rapamycin (mTOR) by amino acids in rat adipocytes. J Cell Biochem. 2000;79:427–41.
Pende M, Kozma SC, Jaquet M, Oorshcot V, Burcelin R, Le Marchand-Brustel Y, Klumperman J, Thorens B, Thomas G. Hypoinsulinemia, glucose intolerance and diminished β-cell size in S6K1-deficient mice. Nature. 2000;408:994–7.
Tremblay F, Krebs M, Dombrowski L, Brehm A, Bernroider E, Roth E, Nowotny P, Waldhausl W, Marette A, Roden M. Overactivation of S6 kinase 1 as a cause of human insulin resistance during increased amino acid availability. Diabetes. 2005;54:2674–84.
Tzatsos A, Kandor KV. Nutrients suppress phosphatidylinositol 3-kinase/Akt signaling via Raptor-dependent mTOR-mediated insulin receptor substrate 1 phosphorylation. Mol Cell Biol. 2006;26:63–76.
Mussig K, Fiedler H, Staiger H, Weigert C, Lehmann R, Schleicher ED, Haring H-U. Insulin-induced stimulation of JNK and the PI 3-kinase/mTOR pathway leads to phosphorylation of serine 318 of IRS-1 in C2C12 myotubes. Biochem Biophys Res Commun. 2005;335:819–25.
Hiratani K, Haruta T, Tani A, Kawahara J, Usui I, Kobayashi M. Roles of mTOR and JNK in serine phosphorylation, translocation, and degradation of IRS-1. Biochem Biophys Res Commun. 2005;335:836–42.
Aguirre V, Uchida T, Yenush L, Davis R, White MF. The c-Jun NH2-terminal kinase promotes insulin resistance during association with insulin receptor substrate-1 and phosphorylation of ser307. J Biol Chem. 2000;275:9047–54.
Hirosumi J, Tuncman G, Chang L, Gorgun CZ, Uysal KT, Maeda K, Karin M, Hotamisligil GS. A central role for JNK in obesity and insulin resistance. Nature. 2002;410:333–6.
Yuan M, Konstantopoulos N, Lee J, Hansen L, Li ZW, Karin M, Shoelson SE. Reversal of obesity- and diet-induced insulin resistance with salicylates or targeted disruption of IKK-beta. Science. 2001;293:1673–7.
Gao Z, Hwang D, Bataille F, Lefevre M, York D, Quon M, Ye J. Serine phosphorylation of insulin receptor substrate 1 by inhibitor kappa B kinase complex. J Biol Chem. 2002;277:48115–21.
Kim F, Tysseling KA, Rice J, Gallis B, Haji L, Giachelli CM, Raines EW, Corson MA, Schwartz MW. Activation of IKKβ by glucose is necessary and sufficient to impair insulin signaling and nitric oxide production in endothelial cells. J Mol Cell Cardiol. 2005;39:327–34.
Ueki K, Fruman DA, Brachmann SM, Tseng YH, Cantley LC, Kahn CR. Molecular balance between the regulatory and catalytic subunits of phosphoinositide 3-kinase regulates cell signaling and survival. Mol Cell Biol. 2002;22:965–77.
Shepherd PR, Withers DJ, Siddle K. Phosphoinositide 3-kinase: the key switch mechanism in insulin signaling. Biochem J. 1998;333:471–90.
Yu J, Zhang Y, McIlroy J, Rordorf-Nikolic T, Orr GA, Backer JM. Regulation of the p85/p110 phosphatidylinositol 3′-kinase: stabilization and inhibition of the p110 alpha catalytic subunit by the p85 regulatory subunit. Mol Cell Biol. 1998;18:1379–87.
Dhand R, Hara K, Hiles I, Bax B, Gout I, Panayotou G, Fry MJ, Yonezawa K, Kasuga M, Waterfield MD. PI 3-kinase: structural and functional analysis of intersubunit interactions. EMBO J. 1994;13:511–21.
Klippel A, Escobedo JA, Hirano M, Williams LT. The interaction of small domains between the subunits of phosphatidylinositol 3-kinase determines enzyme activity. Mol Cell Biol. 1994;14:2675–85.
Hu P, Mondino A, Skolnik EY, Schlessinger J. Cloning of a novel, ubiquitously expressed human phosphatidylinositol 3-kinase and identification of its binding site on p85. Mol Cell Biol. 1993;13:7677–88.
Yu J, Wjasow C, Backer JM. Regulation of the p85/p110α phosphatidylinositol 3′-kinase. J Biol Chem. 1998;273:30199–203.
Shekar SC, Wu H, Fu Z, Yip S-C, Nagajyothi, Cahill SM, Girvin ME, Backer JM. Mechanism of constitutive phosphoinositide 3-kinase activation by oncogenic mutants of the p85 regulatory subunit. J Biol Chem. 2005;280:27850–5.
Fu Z, Aronoff-Spencer E, Wu H, Gerfen GJ, Backer JM. The iSH2 domain of PI 3-kinase is a rigid tether for p110 and not a conformational switch. Arch Biochem Biophys. 2004;432:244–51.
Terauchi Y, Tsuji Y, Satoh S, Minoura H, Murakami K, Okuno A, Inukai K, Asano T, Kaburagi Y, Ueki K, Nakajima H, Hanafusa T, Matsuzawa Y, Sekihara H, Yin Y, Barrett JC, Oda H, Ishikawa T, Akanuma Y, Komuro I, Suzuki M, Yamamura K, Kodama T, Suzuki H, Kadowaki T. Increased insulin sensitivity and hypoglycaemia in mice lacking the p85α subunit of phosphoinositide 3-kinase. Nat Genet. 1999;21:230–5.
Ueki K, Algenstaedt P, Mauvais-Jarvis F, Kahn CR. Positive and negative regulation of phosphoinositide 3-kinase-dependent signaling pathways by three different gene products of the p85α regulatory subunit. Mol Cell Biol. 2000;20:8035–46.
Mauvais-Jarvis F, Ueki K, Fruman DA, Hirshman MF, Sakamoto K, Goodyear LJ, Iannacone M, Accili D, Cantley LC, Kahn CR. Reduced expression of the murine p85α subunit of phosphoinositide 3-kinase improves insulin signaling and ameliorates diabetes. J Clin Invest. 2000;109:141–9.
Ueki K, Fruman DA, Yballe CM, Fasshauer M, Klein J, Asano T, Cantley LC, Kahn CR. Positive and negative roles of p85α and p85β regulatory subunits of phosphoinositide 3-kinase in insulin signaling. J Biol Chem. 2003;278:48453–66.
Barbour LA, Shao J, Qiao L, Leitner W, Anderson M, Friedman JE, Draznin B. Human placental growth hormone increases expression of p85 regulatory unit of phosphatidylinositol 3-kinase and triggers severe insulin resistance in skeletal muscle. Endocrinology. 2004;145:1144–50.
Cornier M-A, Bessesen DH, Gurevich I, Leitner JW, Draznin B. Nutritional up-regulation of p85α expression is an early molecular manifestation of insulin resistance. Diabetologia. 2006;49:748–54.
Giorgino F, Pedrini MT, Matera L, Smith RJ. Specific increase in p85α expression in response to dexamethazone is associated with inhibition of insulin-like growth factor-I stimulated phosphatidylinositol 3-kinase activity in cultured muscle cells. J Biol Chem. 1997;272:7455–63.
Lamia KA, Peroni OD, Kim Y-B, Rameh LE, Kahn BB, Cantley LC. Increased insulin sensitivity and reduced adiposity in phosphatidylinositol 5-phosphate 4-kinase β−/− mice. Mol Cell Biol. 2004;24:5080–7.
Barbour L, Rahman SM, Gurevich I, Leitner JW, Fisher S, Roper M, Knotts T, Vo Y, Yakar S, LeRoith D, Kahn CR, Cantley L, Friedman J, Draznin B. Increased P85alpha is a potent negative regulator of skeletal muscle insulin signaling and induces in vivo insulin resistance associated with growth hormone excess. J Biol Chem. 2005;280:37489–94.
Ueki K, Yballe CM, Brachmann SM, Vicent D, Watt JM, Kahn CR, Cantley LC. Increased insulin sensitivity in mice lacking p85β subunit of phosphoinositide 3-kinase. Proc Natl Acad Sci U S A. 2002;99:419–24.
Luo J, Field SJ, Lee JY, Engelman JA, Cantley LC. The p85 regulatory subunit of phosphoinositide 3-kinase down-regulates IRS-1 signaling via the formation of a sequestration complex. J Cell Biol. 2005;170:455–64.
Kirwan J, Varastehpour A, Jing M, Presley L, Shao J, Friedman JE, Catalano PM. Reversal of insulin resistance post-partum is linked to enhanced skeletal muscle insulin signaling. J Clin Endocrinol Metab. 2004;89:4678–84.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2020 Springer Nature Switzerland AG
About this chapter
Cite this chapter
Draznin, B. (2020). Molecular Mechanisms of Insulin Resistance. In: Zeitler, P., Nadeau, K. (eds) Insulin Resistance. Contemporary Endocrinology. Humana, Cham. https://doi.org/10.1007/978-3-030-25057-7_4
Download citation
DOI: https://doi.org/10.1007/978-3-030-25057-7_4
Published:
Publisher Name: Humana, Cham
Print ISBN: 978-3-030-25055-3
Online ISBN: 978-3-030-25057-7
eBook Packages: MedicineMedicine (R0)